CorMedix Inc. CRMD

Company Overview

CorMedix Inc. is a U.S.-based biopharmaceutical company focused on the development and commercialization of therapeutic products designed to prevent and treat infectious and inflammatory diseases. The company operates primarily within the biotechnology and specialty pharmaceutical industries, with a strategic emphasis on catheter-related bloodstream infection prevention and critical care anti-infective therapies. CorMedix’s principal commercial product is DefenCath, a catheter lock solution intended to reduce bloodstream infections in patients receiving chronic hemodialysis through central venous catheters. The company’s revenue base is currently centered on commercialization activities related to DefenCath and associated licensing, distribution, and product supply arrangements.

CorMedix was founded in 2006 and is headquartered in Berkeley Heights, New Jersey. The company evolved from a broader pharmaceutical development platform into a more specialized anti-infective and renal-care focused biotechnology business. Its positioning is tied to addressing hospital-acquired and catheter-related infections, which represent significant healthcare cost and patient safety concerns. CorMedix’s strategy has emphasized regulatory approval, commercialization partnerships, and expansion within the dialysis and critical care markets.